Polynovo Ltd
PNV: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|^dn@l<S | LOCK|%p | LOCK|qjD$<? |
Polynovo Earnings: Shares Undervalued on Solid Product Demand Despite Currency Headwinds
Polynovo's interim 2026 sales rose a solid 26% to AUD 68 million, driven by a 25% increase in US sales to AUD 52 million. Sales of its new alternative product that has no sealing membrane, Novosorb MTX, almost tripled to AUD 6 million. Underlying EBITDA grew 82% to AUD 5 million on cost control.
